Need professional-grade analysis? Visit stockanalysis.com
$14.77M
N/A
N/A
N/A
Finch Therapeutics Group Inc (FNCH) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $7.66, down 4.25% from the previous close.
Over the past year, FNCH has traded between a low of $7.66 and a high of $14.56. The stock has lost 38.0% over this period. It is currently 47.4% below its 52-week high.
Finch Therapeutics Group Inc has a market capitalization of $14.77M.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. On March 22, 2026, Finch Therapeutics Group, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Side-by-side comparison against top Healthcare peers.